Prothena Corporation plc

Prothena Corporation plc is a late-stage clinical biotechnology company focused on discovering and developing novel therapies for diseases caused by protein dysregulation. Its pipeline includes prasinezumab, an investigational humanized monoclonal antibody in Phase 3 trials for Parkinson's disease and synucleinopathies; coramitug, an antibody in Phase 3 for transthyretin amyloidosis; and BMS-986446, an anti-tau antibody in Phase 2 for Alzheimer's disease. It also has earlier-stage programs such as PRX019 for neurodegenerative diseases, PRX123 a dual Aß-Tau vaccine for Alzheimer's, and PRX012 a next-generation anti-Aß antibody. Additionally, it develops TDP-43 CYTOPE for amyotrophic lateral sclerosis and PRX012-TfR for Alzheimer's. Prothena collaborates with Roche on a-synuclein antibodies and with Bristol Myers Squibb on tau and TDP-43 targets.

Prothena Corporation plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PRTA. Its shares trade in US Dollars (USD). As a company incorporated in Ireland, it reports its financial results in USD, which is the currency of its primary listing exchange.

Prothena operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing therapies for diseases caused by protein dysregulation, including neurodegenerative conditions like Parkinson's and Alzheimer's, as well as amyloidosis. Its late-stage clinical programs target these areas with monoclonal antibodies and vaccines.

Prothena Corporation plc is headquartered in Ireland, as indicated by its country of incorporation. The company operates primarily in the US region (region: us) and serves global markets through its collaborations with partners like Roche and Bristol Myers Squibb. Its therapies target diseases prevalent worldwide, such as Parkinson's disease, Alzheimer's disease, and transthyretin amyloidosis.

Prothena generates revenue through licensing, development, and commercialization agreements with pharmaceutical partners. It has a license and collaboration agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies targeting a-synuclein, including prasinezumab. It also has a master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau and TDP-43. These partnerships provide upfront payments, milestone payments, and royalties on future product sales. The company's pipeline includes both wholly owned programs and partnered assets, with late-stage candidates like prasinezumab and coramitug advancing toward potential regulatory approval.